Upregulation of CIP2A in estrogen depletion-resistant breast cancer cells treated with low-dose everolimus

Eiji Nishio¹, Takanori Hayashi², Mao Akaza², Yukiko Hisatomi², Masahiro Hikichi³, Takuma Fujii¹, Toshiaki Utsumi³, Nobuhiro Harada² and Yohei Shimono²

¹ Department of Obstetrics and Gynecology, Fujita Health University School of Medicine, Toyoake, Japan
² Department of Biochemistry, Fujita Health University School of Medicine, Toyoake, Japan
³ Department of Breast Surgery, Fujita Health University School of Medicine, Toyoake, Japan

Keywords
Akt; breast cancer; CIP2A; estrogen receptor; everolimus

Correspondence
T. Hayashi, Department of Biochemistry, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi 470-1192, Japan
E-mail: thayashi@fujita-hu.ac.jp

Eiji Nishio and Takanori Hayashi contributed equally to this work

(Received 29 November 2019, revised 31 July 2020, accepted 16 August 2020)

doi:10.1002/2211-5463.12956

Everolimus (EVE), an inhibitor of mammalian target of rapamycin, is an emerging second-line therapeutic option for hormone therapy-resistant breast cancers. However, some patients do not respond to EVE, whereas in others it exacerbates the disease. Cellular inhibitor of protein phosphatase 2A (CIP2A) is a human oncoprotein that can promote cancer cell growth and apoptosis resistance. Although CIP2A is upregulated in hormone-related cancers, such as breast cancer, little is known about potential anti-tumor effects of downregulating CIP2A. As a model to study the resistance of breast cancer cells to hormone treatment, we previously established clones of long-term estrogen depletion-resistant MCF-7 (LTED) cells. Here, we selected three clones highly responsive to EVE and three clones poorly responsive to EVE. When cells were treated with EVE, CIP2A mRNA expression was decreased in highly responsive EVE clones (DC-cells) whereas it was increased in poorly responsive EVE clones (IC-cells). Using Kaplan–Meier survival plots, we report that high expression of CIP2A was associated with significantly reduced overall survival in patients with luminal A breast cancer. In IC-cells, cell growth was enhanced upon EVE treatment whereas an EVE range of 0.1–100 nm decreased growth in DC-cells. The mRNA expression of genes involved in epithelial–mesenchymal transition (EMT) such as CDH1, CLDN3, and CK19 was significantly decreased in IC-cells, but remained unchanged in DC-cells. These findings highlight a relationship between CIP2A and EMT in the intrinsic resistance of hormone therapy-resistant breast cancers to EVE.

Breast cancer is one of the most common malignancies in women, with an incidence of 2.1 million cases and 0.63 million deaths worldwide in 2018 [1]. It is classified into four types according to the status of expression of hormone receptors. The most common type is the estrogen receptor alpha (ERα)-positive breast cancer, called the ‘luminal type’. Estrogen plays a crucial role in the development and progression of ERα-positive breast cancers [2,3].

Aromatase inhibitors (AIs) which target aromatase, an enzyme involved in the conversion of androgen into estrogen in the body, is a commonly used therapeutic option as hormone treatment (HT) [4–8] in patients with ERα-positive breast cancers. AIs generally have

Abbreviations
AIs, Aromatase inhibitors; CIP2A, Cellular inhibitor of protein phosphatase 2A; DC-cells, Highly responsive EVE LTED clones; EMT, Epithelial–mesenchymal transition; EVE, Everolimus; IC-cells, Poorly responsive EVE LTED clones; LTED, Long-term estrogen depletion-resistant MCF-7.
fewer side effects and significantly improved efficacy when compared to the currently used breast cancer treatments. Much of the recent research on AIs focuses on determining the mechanisms of resistance to these inhibitors [9–12].

One of the major reasons why ER-positive breast cancer develops resistance to AIs is the abnormal activation of ER. The estrogen-independent aberrant activation of ERα has been shown to occur upon its phosphorylation at serine 167 (S167) through the phosphatidylinositol 3-kinase-Akt-mTOR signaling pathway [13–15]. Everolimus (EVE), an inhibitor of mammalian target of rapamycin (mTOR), is commonly used to treat HT-resistant breast cancers [13–17]. The Breast Cancer Trials of Oral Everolimus-2 (BOLERO-2) study showed that the addition of EVE to estrogen depletion therapy significantly improved progression-free survival, with observed medians of 6.9 and 2.8 months. The results of the BOLERO2 trial demonstrated that EVE improves the treatment of HT-resistant breast cancer [18].

As a model to study the resistance of breast cancer cells to HT, we previously established 30 clones of long-term estrogen depletion-resistant MCF-7 (LTED) cells. In these cells, we found that the effects of an Akt activator, cellular inhibitor of protein phosphatase 2A (CIP2A), and those of EVE strongly correlated with each other [18,19]. CIP2A inactivates protein phosphatase 2A (PP2A), which upregulates Akt [20]. It is also a characteristic human oncoprotein that can promote the growth of cancer cells, anchorage-independent cell growth, and apoptosis resistance [21,22]. PP2A is frequently inactivated in human cancers, resulting in the induction of epithelial–mesenchymal transition (EMT) and reduction of E-cadherin and p53 expression [21]. Although the expression of CIP2A is upregulated in hormone-related cancers, such as breast cancer, little is known about the effects of specific molecular targeted therapy on the expression of CIP2A.

Our previous studies showed that the proliferative capacity of Highly responsive EVE LTED clones (DC-cells) was suppressed at low concentrations of EVE (IC_{50} < 1.5 nm), whereas that of Poorly responsive EVE LTED clones (IC-cells) was not affected even at high EVE concentrations (IC_{50} > 200 nm) [19]. In this study, we investigated whether low concentrations EVE (0.01 nm) affect the proliferation of three strains of LTED cells in which CIP2A was increased (increased CIP2A cells: IC-cells) and three strains in which CIP2A was decreased (decreased CIP2A cells: DC-cells).

**Materials and methods**

**Cell culture**

MCF-7 cells (human ERα-positive breast cancer cells) were obtained from the American Type Culture Collection (Manassas, VA, USA) and cultured as described previously [19]. To avoid the hormonal effects of phenol red and serum, cells treated with 17 beta-estradiol (E2) were cultured in phenol red-free RPMI 1640 medium supplemented with 10% dextran-coated charcoal-treated FBS (Nichirei Biosciences, Inc., Tokyo, Japan). LTED cells, which model estrogen depletion-resistant cells, were established as described previously [23–25].

**Cell proliferation assay**

The viability of cultured cells was determined using a CCK-8 kit (Doxid Molecular Technologies, Kumamoto, Japan) to evaluate the effect of EVE (0.01, 0.1, 1, 10, and 100 nm, Wako Pure Chemical Industries, Ltd., Osaka, Japan) on LTED cells as described previously [19]. Briefly, cells (1000 cells/well) were seeded in 96-well plates and cultured in medium supplemented with one or more drugs at 37 °C in a 5% CO₂ incubator for 96 h.

**Western blotting**

Whole-cell lysates were prepared using lysis buffer (62.5 mM Tris/HCl, pH 6.8, 5% 2-mercaptoethanol, 2% sodium dodecyl sulfate, 5% sucrose, and 0.01% bromophenol blue; Wako Pure Chemical Industries, Ltd.), and the concentration of proteins in the lysates was measured using a DC T™ Protein Assay kit (Bio-Rad Laboratories, Inc., Hercules, CA, USA) as described previously [19]. The samples (5 μg protein/lane) were separated by electrophoresis on 10% SDS/PAGE and transferred to polyvinylidene difluoride (PVDF) membranes (GE Healthcare, Piscataway, NJ, USA). The PVDF membranes were processed as described previously [19]. The antibodies used were rabbit polyclonal and monoclonal antibodies against Akt (1 : 2000 dilution), phosphorylated Akt Ser473 (1 : 1000 dilution), Rb (1 : 1000 dilution), phosphorylated Rb (1 : 1000 dilution), and CIP2A (1 : 1000 dilution) (all obtained from Cell Signaling Technology, Inc., Danvers, MA, USA), and horseradish peroxidase-labeled secondary anti-rabbit (1 : 10 000 dilution; Bio-Rad Laboratories) or anti-mouse (1 : 5000 dilution; MBL, Nagoya, Japan) antibodies. The intensity of the chemiluminescence of specific bands was quantified using COOL SAYER software (ATTO, Tokyo, Japan). Rabbit polyclonal antibodies against GAPDH (1 : 2000 dilution) were purchased from Santa Cruz Biotechnology (Santa Cruz Biotechnology, Dallas, TX, USA). All antibodies were diluted in Can Get Signal® Immunoreaction Enhancer Solution (Toyobo, Inc., Osaka, Japan).

**Immunofluorescence analysis**

Long-term estrogen depletion-resistant MCF-7 cells were seeded on cover slips and allowed to adhere overnight. After incubation with DMSO or EVE (100 nm) for 72 h, the cells
were fixed with 4% paraformaldehyde in PBS, permeabilized in 0.1% Tween 20/PBS, and blocked with 1% BSA. The cells were washed and incubated with anti-human E-cadherin (1:100 dilution), cytokeratin 19 (CK19, 1:100 dilution), and ZEB1 (1:50 dilution) antibodies (all obtained from Cell Signaling Technology, Inc.) for 2 h at room temperature. The cells were subsequently washed and incubated with Alexa488-labeled anti-rat secondary antibody (Invitrogen, Carlsbad, CA, USA) for 2 h. After staining the nuclei with DAPI, the cells were visualized using a fluorescence microscope, BZ-9000 (Keyence Corporation, Osaka, Japan).

RNA extraction and quantitative PCR
Total RNA was extracted from treated cells using TRIzol reagent (Qiagen, Hilden, Germany) and reverse-transcribed using the PrimeScript RT reagent kit (Takara Bio, Inc., Shiga, Japan). Quantitative PCR was performed in triplicate using the ABI Perkin-Elmer Prism 7300HT Sequence detection system (Applied Biosystems, Foster City, CA, USA). TaqMan gene expression assays (Applied Biosystems) were used to detect the expression of CIP2A (TaqMan Accession ID Hs00405413_m1), CDH1 (Hs999999905_m1), CLDN3 (Hs999999905_m1), CK19 (Hs999999905_m1), and ZEB1 (Hs999999905_m1); GAPDH (Hs999999905_m1) was used as an internal control gene. Relative expression levels were determined using the ΔΔCt method, according to the manufacturer’s instructions.

Statistical analysis
Results were analyzed for statistical significance using one-way analysis of variance followed by Fisher’s protected least significant difference test when the data were derived from more than two groups. For significance tests based on three groups or more, subsequent analysis with a post hoc test with the Bonferroni correction was performed. The paired Student’s t-test was performed where indicated, and P-values of < 0.05 were considered statistically significant.

Results
CIP2A is a predictor of poor prognosis in patients with ER-positive, HER2-negative breast cancer
To analyze the effects of CIP2A expression in patients with ER-positive breast cancer, we used the Kaplan–Meier plotter database (http://kmplot.com/), which is commonly used in cancer research [26,27], to predict prognostic value. CIP2A is referred to as KIAA1524 in the Kaplan–Meier plotter (Fig. 1). The overall survival (OS) of 153 patients with basal-like (ER-/HER2−) and 271 patients with luminal A (ER+/HER2−) breast cancer was analyzed using the Kaplan–Meier survival plot. High expression of CIP2A was associated with significantly reduced OS in patients with luminal A breast cancer [hazard ratio = 1.98 (1.18–3.32), P < 0.01] but
not in patients with basal-like breast cancer [hazard ratio = 0.63 (0.33–1.20), \( P = 0.156 \)]. These results suggest that the relationship between CIP2A expression and therapeutic effect might be specific for ER\(\alpha\)-positive breast cancer.

Low doses of EVE increase the expression of CIP2A in EVE-resistant breast cancer cells

We previously established 30 clones of LTED cells and performed drug sensitivity assays to determine the half-maximal inhibitory concentration (IC\(_{50}\)) for EVE in each clone [18,19]. To further evaluate the effect of EVE on CIP2A mRNA expression, we selected three LTED clones (DC-cells: clone number L3, L5, and L22) highly responsive to EVE and three clones (IC-cells: clone number L4, L7, and L29) poorly responsive to EVE.

These cells were incubated with or without EVE (0.01 or 10 nm) for 72 h. The mRNA expression levels of CIP2A were significantly increased in cells that were poorly responsive to EVE and treated with 0.01 nm EVE (Fig. 2A). The relative expression levels of CIP2A in each LTED cell line exposed to EVE are shown in Fig. 2B.C. CIP2A levels in three LTED clones that were highly responsive to EVE were reduced by treatment with 10 nm EVE. This result is consistent with the findings of our previous study [13]. However, this experiment revealed that low concentrations of EVE (0.01 nm EVE) increased the expression of CIP2A in poorly responsive LTED cells. Therefore, the three clones in which CIP2A expression was increased by EVE were referred to as IC-cells, whereas the three clones in which CIP2A expression was increased by EVE were indicated as DC-cells. Next, we examined whether cells with increased CIP2A expression activated the Akt signaling and consequently affected the phosphorylation of Rb. The level of CIP2A in IC-cells was increased by 0.01 nm EVE. In these IC-cells, the levels of both phosphorylated Akt and phosphorylated Rb were increased (Fig. 2D).
Low concentrations of EVE increase the proliferation of IC-cells

Because higher expression levels of CIP2A were associated with poorer prognosis and low concentrations of EVE-activated Akt signaling in IC-cells (Figs 1 and 2), we next analyzed whether EVE increases the proliferation of IC-cell clones [19]. Both IC- and DC-cells were incubated with or without EVE (0.01, 0.1, 1, and 100 nM) for 4 days. The number of cells increased significantly when the cells were exposed to 0.01, 0.1, and 1 nM EVE (Fig. 3). In contrast, in the clones that were highly responsive to EVE, the number did not increase when the cells were exposed to 0.01 nM EVE and it rather decreased when 0.1–100 nM EVE was added (Fig. 4).

Low concentrations of EVE enhance EMT in IC-cells

CIP2A is known to promote EMT by reducing the number of epithelial cancer cells [20,21]. We selected two clones that were highly responsive to EVE, DC-cells (clone numbers L3 and L5), and two clones that were poorly responsive to EVE, IC-cells (clone numbers L4 and L7). The cells were incubated with or without EVE (0.01 nM) for 48 h. There was no significant change in the mRNA expression levels of CDH1, CLDN3, or CK19 in DC-cells (Fig. 5A). In contrast, the mRNA expression levels of CDH1, CLDN3, and CK19 were significantly decreased in all IC-cells (Fig. 5B).

To further confirm the effect of EVE (0.01 nM) on EMT, the expression of E-cadherin, CK19, and ZEB1 in DC-cells (L5) and IC-cells (L7) was verified using immunofluorescent staining (Fig. 5C). ZEB1 is expressed in most human cancers in epithelial tissues. EVE treatment decreased the expression of E-cadherin and CK19 and increased the expression of ZEB1 in IC-cells (L7). In contrast, E-cadherin in DC-cells (L5) was slightly increased by EVE treatment.

Discussion

Everolimus is a molecular targeting drug developed to overcome HT resistance. However, 15% of cancers are EVE-resistant at the beginning of treatment [28]. Previous studies using multiple LTEDs showed that EVE increases the expression levels of CIP2A and that CIP2A-mediated activation of Akt signaling counteracts the effect of EVE [19–22]. EVE is inhibited
in vitro by pS6 kinase in a concentration-dependent manner (IC$_{50}$: 0.1–100 nM) [28]. Therefore, it is orally administered at a maximum dose of 10 mg (0.1 mmol) per day. It was also determined that this drug acts at a concentration of 0.3 nM or less in the patient’s body. In this study, we found that in EVE-resistant clones (IC-cells), even very low concentrations (0.01–1 nM) of EVE increased the expression of CIP2A, which in turn induced the phosphorylation of Rb. Using six LTED clones, we observed that minimal concentrations (0.01–100 nM) of EVE promoted cell growth (Fig. 3). Moreover, our data suggest that EVE induces EMT and proliferation in EVE-resistant breast cancer. This study was conducted based on the concentration of EVE used by patients. Therefore, the enhanced EMT observed in IC-cells may occur in patients with EVE resistance (Fig. 6).

CIP2A is a novel oncoprotein driving the malignant phenotype through and has been reported to be overexpressed in 39% of breast cancer cases [29]. It has also emerged as a neoplastic protein that is generally overexpressed in many tumors and correlates with higher tumor grade and resistance to treatment. CIP2A also induces EMT and is associated with drug resistance [21]. Moreover, the expression of CIP2A may be useful as a novel prognostic and predictive indicator of tamoxifen resistance and recurrence in ER-positive breast cancer [30]. Our findings indicate that EVE can cause disease progression via CIP2A, suggesting that CIP2A can be used as a potential

---

**Fig. 4.** Effect of low concentrations of EVE on the proliferation of DC-cells. The viability of cells highly responsive to EVE was assessed when exposed to EVE; L3, L5, L18, L22, L23, and L26 are LTED clones, with an IC$_{50}$ lower than 5 nM. These clones were incubated with or without EVE (0.01, 0.1, 1, and 100 nM). The medium was changed every 2 days. The number of cells was measured with a CCK-8 kit (n = 3 per treatment group). Data represent means ± SD of three independent experiments (Student’s t-test; *P < 0.05; **P < 0.01).

**Fig. 5.** Effect of low concentrations of EVE on EMT in DC- and IC-cells. Clone numbers L3 and L5 (indicated as DC-cells) and L7 and L4 (indicated as IC-cells) were assessed. DC- and IC-cells were incubated with or without EVE (0.01 nM) for 48 h. The relative mRNA levels of CDH1, CLDN3, and CK19 were evaluated in DC- and IC-cells treated with EVE at the concentrations indicated. GAPDH was used for normalization. (A) mRNA expression levels of CDH1, CLDN3, and CK19 in L3 and L5 cells (n = 3 per treatment group). Data represent means ± SD of three independent experiments (Student’s t-test; *P < 0.05). (B) mRNA expression levels of CDH1, CLDN3, and CK19 in L4 and L7 cells (n = 3 per treatment group). Data represent means ± SD of three independent experiments (Student’s t-test; *P < 0.05). (C) Expression levels of E-cadherin, CK19, and ZEB1 in DC-cells (L5) and IC-cells (L7). Representative pictures of tumor cells and EVE are shown (n = 1). Scale bar: 20 μm.
Upregulation of CIP2A and everolimus treatment

E. Nishio et al.

A. DC-cells

- **CDH1**
  - L3: Cont, EVE
  - L5: Cont, EVE

- **CLDN3**
  - L3: Cont, EVE
  - L5: Cont, EVE

- **CK19**
  - L3: Cont, EVE
  - L5: Cont, EVE

- **ZEB1**
  - L3: Cont, EVE
  - L5: Cont, EVE

B. IC-cells

- **CDH1**
  - L4: Cont, EVE
  - L7: Cont, EVE

- **CLDN3**
  - L4: Cont, EVE
  - L7: Cont, EVE

- **CK19**
  - L4: Cont, EVE
  - L7: Cont, EVE

- **ZEB1**
  - L4: Cont, EVE
  - L7: Cont, EVE

C. Immunofluorescence images

|          | E-cadherin / DAPI | CK-19 / DAPI | ZEB1 | ZEB1 / DAPI |
|----------|------------------|-------------|------|-------------|
| **DC-cells** (L 5) | ![Image](image1.png) | ![Image](image2.png) | ![Image](image3.png) | ![Image](image4.png) |
| Cont     | ![Image](image5.png) | ![Image](image6.png) | ![Image](image7.png) | ![Image](image8.png) |
| EVE (0.01nM) | ![Image](image9.png) | ![Image](image10.png) | ![Image](image11.png) | ![Image](image12.png) |

| **IC-cells** (L 7) | ![Image](image13.png) | ![Image](image14.png) | ![Image](image15.png) | ![Image](image16.png) |
| Cont     | ![Image](image17.png) | ![Image](image18.png) | ![Image](image19.png) | ![Image](image20.png) |
| EVE (0.01nM) | ![Image](image21.png) | ![Image](image22.png) | ![Image](image23.png) | ![Image](image24.png) |
biomarker to optimize treatment of HT-resistant breast cancers.

Acknowledgements

This work was supported in part by Grants-in-Aid for Scientific Research from the Aichi Cancer Research Foundation (grant no. 2-12). TH was also supported by funding from a Grant-in-Aid for Young Scientists (B), 2017-2019 (No. 17K16172).

Conflict of interest

The authors declare no conflict of interest.

Data Accessibility

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Author contributions

Most of the experiments were performed by TH. EN, MA, YH, and MH conducted the experiments and performed the data analysis. YS, NH, TU, and TF participated in the designing of the experiments and supervised the study. All authors read and approved the final manuscript.

References

1 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68, 394–424.
2 Platet N, Cathiard AM, Gleizes M and Garcia M (2004) Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion. Crit Rev Oncol Hematol 51, 55–67.
3 Klinge CM (2001) Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res 29, 2905–2919.
4 He T, Yang W, Zhang X, Li P, Yang D, Wu Y, Fan Y, Xiang M, Huang Q, Chen J et al. (2020) Comparative effectiveness of tamoxifen, toremifene, letrozole, anastrozole, and exemestane on lipid profiles in breast cancer patients: a network meta-analysis. Medicine 99, e18550.
5 Lin NU and Winer EP (2008) Advances in adjuvant endocrine therapy for postmenopausal women. J Clin Oncol 26, 798–805.
6 Joerger M and Thürlimann B (2009) Update of the BIG 1–98 trial: where do we stand? Breast 18 (suppl 3), S78–S82.
7 Giobbie-Hurder A, Price KN, Gelber RDG and International Breast Cancer Study, B.I.G.C. Group (2009) Design, conduct, and analyses of Breast International Group (BIG) 1–98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer. Clin Trials 6, 272–287.
8 Caroso F, Costa A, Senkus EM, Aapro F, Andre CH, Barrios J, Bergh G, Bhattacharyya L, Biganzoli MJ, Cardoso L et al. (2017) 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3). Ann Oncol 28, 16–33.
9 Jones RH, Casbard A, Carucci M, Cox C, Butler R, Alchami F, Madden TA, Bale C, Beecy C, Joffe J et al. (2020) Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 21, 345–357.
10 Hanker AB, Sudhan DR and Arteaga CL (2020) Overcoming endocrine resistance in breast cancer. Cancer Cell 37, 496–513.
11 Hanamura T and Hayashi SI (2018) Overcoming aromatase inhibitor resistance in breast cancer: possible
mechanisms and clinical applications. *Breast Cancer* **25**, 379–391.
12 Becker MA, Ibrahim YH, Cui X, Lee AV and Yee D (2011) The IGF pathway regulates ERalpha through a S6K1-dependent mechanism in breast cancer cells. *Mol Endocrinol* **25**, 516–528.
13 Yamnik RL, Digilova A, Davis DC, Brodt ZN, Murphy CJ and Holz MK (2009) S6 kinase I regulates estrogen receptor alpha in control of breast cancer cell proliferation. *J Biol Chem* **284**, 6361–6369.
14 Boulay A, Rudloff J, Ye J, Zumstein-Mecker S, O’Reilly T, Evans DB, Chen S and Lane HA (2005) Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. *Clin Cancer Res* **11**, 5319–5328.
15 Ma CX, Reinert T, Chmielewska I and Ellis MJ (2015) Mechanisms of aromatase inhibitor resistance. *Nat Rev Cancer* **15**, 261–275.
16 Du L, Li X, Zhen L, Chen W, Mu L, Zhang Y and Song A (2018) Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway. *Mol Med Rep* **17**, 7163–7169.
17 Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Grant M, Pritchard KI, Lebrun F et al. (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. *N Engl J Med* **366**, 520–529.
18 Hayashi T, Hikichi M, Yukitake J, Harada N and Utsumi T (2017) Estradiol suppresses phosphorylation of ERalpha serine 167 through upregulation of PP2A in breast cancer cells. *Oncol Lett* **14**, 8060–8065.
19 Hayashi T, Hikichi M, Yukitake J, Wakatsuki T, Nishio E, Utsumi T and Harada N (2018) Forskolin increases the effect of everolimus on aromatase inhibitor-resistant breast cancer cells. *Oncotarget* **9**, 23451–23461.
20 Li W, Ge Z, Liu C, Liu Z, Björkholm M, Jia J and Xu D (2008) CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells. *Clin Cancer Res* **14**, 3722–3728.
21 Junntilla MR, Puustinen P, Niemelä M, Ahola R, Arnold H, Böttzauw T, Alaha R, Nielsen C, Ivaska J, Taya Y et al. (2007) CIP2A inhibits PP2A in human malignancies. *Cell* **130**, 51–62.
22 Wang J, Okkeri J, Pavic K, Wang Z, Kauko O, Halonen T, Sarek G, Ojala PM, Rao Z, Xu W et al. (2017) Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56. *EMBO Rep* **18**, 437–450.
23 Santen RJ, Song RX, Zhang ZR, Kumar MH, Jeng A, Masamura J Jr, Lawrence J, Berstein L and Yue W (2005) Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity. *Endocr Relat Cancer* **12** (suppl 1), S61–S73.
24 Martin LA, Farmer I, Johnston SR, Ali S, Marshall C and Dowsett M (2003) Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. *J Biol Chem* **278**, 30458–30468.
25 Yuanxi Z, Xiaobei Z, Yan L, Sheng Z, Jingjing L, Yi M and Jin Z. Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo. *Tumor Biol* **33**, 1349–1362.
26 Gyorffy B, Surowiak P, Budczies J and Lanczky A (2013) Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. *PLoS One* **8**, e82241.
27 Gyorffy B, Pongor L, Bottai G, Li X, Budczies J, Szabo A, Hatzis C, Pusztai L and Santarpia L (2018) An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes. *Br J Cancer* **118**, 1107–1114.
28 Beaver JA and Park BH (2012) The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer. *Future Oncol* **8**, 651–657.
29 Côme C, Laine A, Charron M, Edgren H, Mattila E, Liu X, Jonkers J, Ivaska J, Isola J, Darbon JM et al. (2009) CIP2A is associated with human breast cancer aggressivity. *Clin Cancer Res* **15**, 5092–5100.
30 Ma N, Zhang L, Bian JM and Cao HY (2013) CIP2A expression is associated with altered expression of epithelial-mesenchymal transition markers and predictive of poor prognosis in pancreatic ductal adenocarcinoma. *Tumour Biol* **34**, 2309–2313.